Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy – Nasdaq
|
Humanigen Announces Preclinical Findings Presented on Lenzilumab's Potential to Optimize CAR–T Therapy
Nasdaq Lenzilumab effectively neutralizes GM-CSF. CAR–T cells maintained robust anti-tumor activity in combination with lenzilumab. GM-CSF depletion by lenzilumab may increase CAR-T expansion. BRISBANE, Calif., May 02, 2018 (GLOBE NEWSWIRE) — Humanigen, Inc … |
